🇺🇸 SECGSK plcDoubao · 实盘不做把握 9/10不做原因:不是事件🔁 +1 同一事件
北京时间·🕒 发布 18:27:47·⟳ 抓取 18:28:19 +32s·⚡ 决策 10-13 18:29:06 +47s·14.2 天前
GSK 提交 6-K：多名高管仅经股息再投资与员工持股计划零星买入股票，属例行持股披露
这是法定的管理层交易例行备案：全部为股息再投资、Share Reward Plan 配额和储蓄计划自动成交，单笔仅个位数至千余股，不含任何自主择时增持、业绩、指引或经营增量信息，对 GSK 估值无影响，无多空 edge。
📄 原文GSK plc↗ 原文
----- a6194y.htm ----- 6-K 1 a6194y.htm DIRECTOR/PDMR SHAREHOLDING a6194y UNITED STATES SECURITIES AND EXCHANGE COMMISS…
不做 GSK plc（GSK.GB）
例行 PDMR 持股披露：全部为股息再投资/员工持股/储蓄计划自动成交的零星买入(CEO 仅 3 股)，无自主增持、无基本面或指引增量，金额相对市值可忽略，无 edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
GSK 6-K 只是多名高管经股息再投资与员工持股计划被动买入零星股票(CEO 仅 3 股)的例行 MAR 第19条披露，属行政备案而非信号，不构成交易。
🔎 新鲜度:最早出现 2026-10-12 · 扩散 low · price-in 风险 low ↗
关键理由
- 全部交易为 DRiP/Share Reward Plan/储蓄计划自动成交，非高管 discretionary 增持，不传递基本面或信心信号。
- 数量金额微小(多为 £50–£2 万)，相对 GSK 千亿级市值可忽略，无 materiality。
主要风险
- 若后续出现高管真金白银的大规模自主开放市场买入(非计划内)，需另行评估，与本备案无关。
先例如何影响了这次决策
对本次决策的影响:确认直接 AVOID，不进入标的或仓位选择。
方向:无可参照先例，也无必要：例行计划内微量管理层交易备案历史上不构成可交易事件。
涨幅量级:不足以校准任何幅度，事件无信息含量。
形态:不适用。
原文全文
展开原文 · 27,714 字
----- a6194y.htm -----
6-K
1
a6194y.htm
DIRECTOR/PDMR SHAREHOLDING
a6194y
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of October 2026
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc (the ‘Company’)
Transaction notification
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
Luke Miels
b)
Position/status
Chief Executive Officer
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 October 2026 on shares held
through the Company’s Share Reward Plan
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£17.5852
3
d)
Aggregated
information
Aggregated
volume
Price
N/A (single transaction)
e)
Date
of the transaction
2026-10-08
f)
Place
of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
Lynn Baxter
b)
Position/status
President, Europe
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 October 2026 on shares held
through the Company’s Share Reward Plan
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£17.5852
39
d)
Aggregated
information
Aggregated
volume
Price
N/A (single transaction)
e)
Date
of the transaction
2026-10-08
f)
Place
of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
James Ford
b)
Position/status
SVP and Group General Counsel, Legal and Compliance
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 October 2026 on shares held
through the Company’s Share Reward Plan
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£17.5852
13
d)
Aggregated
information
Aggregated
volume
Price
N/A (single transaction)
e)
Date
of the transaction
2026-10-08
f)
Place
of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
David Redfern
b)
Position/status
President Corporate Development
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 October 2026 on shares held
through the Company’s Share Reward Plan
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£17.5852
80
d)
Aggregated
information
Aggregated
volume
Price
N/A (single transaction)
e)
Date
of the transaction
2026-10-08
f)
Place
of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
Regis Simard
b)
Position/status
President, Global Supply Chain
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 October 2026 on shares held
through the Company’s Share Reward Plan
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£17.5852
32
d)
Aggregated
information
Aggregated
volume
Price
N/A (single transaction)
e)
Date
of the transaction
2026-10-08
f)
Place
of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
Philip Thomson
b)
Position/status
President, Global Affairs
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 October 2026 on shares held
through the Company’s Share Reward Plan
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£17.5852
52
d)
Aggregated
information
N/A (single transaction)
Aggregated
volume
Price
e)
Date
of the transaction
2026-10-08
f)
Place
of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
Deborah Waterhouse
b)
Position/status
CEO, ViiV Healthcare and President, Global Health, GSK
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 October 2026 on shares held
through the Company’s Share Reward Plan
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£17.5852
66
d)
Aggregated
information
Aggregated
volume
Price
N/A (single transaction)
e)
Date
of the transaction
2026-10-08
f)
Place
of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
Victoria Whyte
b)
Position/status
SVP & Company Secretary
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 October 2026 on shares held
through the Company’s Share Reward Plan
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£17.5852
62
d)
Aggregated
information
Aggregated
volume
Price
N/A (single transaction)
e)
Date
of the transaction
2026-10-08
f)
Place
of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
Neil Falkingham
b)
Position/status
PCA of Lynn Baxter (President, Europe)
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 October 2026 on shares held
through the Company’s Share Reward Plan
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£17.5852
64
d)
Aggregated
information
Aggregated
volume
Price
N/A (single transaction)
e)
Date
of the transaction
2026-10-08
f)
Place
of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
Victoria Whyte
b)
Position/status
SVP & Company Secretary
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 October 2026
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£17.5904
243
d)
Aggregated
information
Aggregated
volume
Price
N/A (single transaction)
e)
Date
of the transaction
2026-10-08
f)
Place
of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
Iain Whyte
b)
Position/status
PCA of Victoria Whyte (SVP & Company Secretary)
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 October 2026
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£17.5904
1,182
d)
Aggregated
information
Aggregated
volume
Price
N/A (single transaction)
e)
Date
of the transaction
2026-10-08
f)
Place
of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
Maya Martinez-Davis
b)
Position/status
President, US
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
American Depositary Shares (‘ADS’)
ISIN: US37733W2044
b)
Nature
of the transaction
Acquisition of notional ADS within Ms Martinez-Davis’s GSK
Executive Supplemental Savings Plan account
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
$47.0200
10.155
d)
Aggregated
information
Aggregated
volume
Price
N/A (single transaction)
e)
Date
of the transaction
2026-10-07
f)
Place
of the transaction
New York Stock Exchange (XNYS)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
Lynn Baxter
b)
Position/status
President, Europe
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
Acquisition of Ordinary Shares under the Company’s Share
Reward Plan
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£17.6539
7 (partnership shares)
£17.6539
7 (matching shares)
d)
Aggregated
information
Aggregated
volume
Price
14 Ordinary Shares
£17.6539
e)
Date
of the transaction
2026-10-09
f)
Place
of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
Julie Brown
b)
Position/status
Chief Financial Officer
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
Acquisition of Ordinary Shares under the Company’s Share
Reward Plan
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£17.6539
7 (partnership shares)
£17.6539
7 (matching shares)
d)
Aggregated
information
Aggregated
volume
Price
14 Ordinary Shares
£17.6539
e)
Date
of the transaction
2026-10-09
f)
Place
of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
James Ford
b)
Position/status
SVP and Group General Counsel, Legal and Compliance
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
Acquisition of Ordinary Shares under the Company’s Share
Reward Plan
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£17.6539
7 (partnership shares)
£17.6539
7 (matching shares)
d)
Aggregated
information
Aggregated
volume
Price
14 Ordinary Shares
£17.6539
e)
Date
of the transaction
2026-10-09
f)
Place
of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
David Redfern
b)
Position/status
President, Corporate Development
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
Acquisition of Ordinary Shares under the Company’s Share
Reward Plan
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£17.6539
7 (partnership shares)
£17.6539
7 (matching shares)
d)
Aggregated
information
Aggregated
volume
Price
14 Ordinary Shares
£17.6539
e)
Date
of the transaction
2026-10-09
f)
Place
of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
Regis Simard
b)
Position/status
President, Global Supply Chain
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
Acquisition of Ordinary Shares under the Company’s Share
Reward Plan
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£17.6539
7 (partnership shares)
£17.6539
7 (matching shares)
d)
Aggregated
information
Aggregated
volume
Price
14
Ordinary Shares
£17.6539
e)
Date
of the transaction
2026-10-09
f)
Place
of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
Philip Thomson
b)
Position/status
President, Global Affairs
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
Acquisition of Ordinary Shares under the Company’s Share
Reward Plan
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£17.6539
7 (partnership shares)
£17.6539
7 (matching shares)
d)
Aggregated
information
Aggregated
volume
Price
14 Ordinary Shares
£17.6539
e)
Date
of the transaction
2026-10-09
f)
Place
of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
Deborah Waterhouse
b)
Position/status
CEO, ViiV Healthcare and President, Global Health, GSK
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
Acquisition of Ordinary Shares under the Company’s Share
Reward Plan
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£17.6539
7 (partnership shares)
£17.6539
7 (matching shares)
d)
Aggregated
information
Aggregated
volume
Price
14 Ordinary Shares
£17.6539
e)
Date
of the transaction
2026-10-09
f)
Place
of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
Victoria Whyte
b)
Position/status
SVP & Company Secretary
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
Acquisition of Ordinary Shares under the Company’s Share
Reward Plan
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£17.6539
7 (partnership shares)
£17.6539
7 (matching shares)
d)
Aggregated
information
Aggregated
volume
Price
14 Ordinary Shares
£17.6539
e)
Date
of the transaction
2026-10-09
f)
Place
of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
Neil Falkingham
b)
Position/status
PCA of Lynn Baxter (President, Europe)
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
Acquisition of Ordinary Shares under the Company’s Share
Reward Plan
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£17.6539
7 (partnership shares)
£17.6539
7 (matching shares)
d)
Aggregated
information
Aggregated
volume
Price
14 Ordinary Shares
£17.6539
e)
Date
of the transaction
2026-10-09
f)
Place
of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
David Redfern
b)
Position/status
President Corporate Development
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 October 2026
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£17.6650
7
d)
Aggregated
information
Aggregated
volume
Price
N/A (single transaction)
e)
Date
of the transaction
2026-10-09
f)
Place
of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
Neil Falkingham
b)
Position/status
PCA of Lynn Baxter (President, Europe)
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 October 2026
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£17.6650
7
d)
Aggregated
information
Aggregated
volume
Price
N/A (single transaction)
e)
Date
of the transaction
2026-10-09
f)
Place
of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
David Redfern
b)
Position/status
President Corporate Development
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 October 2026 on Ordinary Shares
held within an ISA
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£17.6650
20
d)
Aggregated
information
Aggregated
volume
Price
N/A (single transaction)
e)
Date
of the transaction
2026-10-09
f)
Place
of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
Victoria Whyte
b)
Position/status
SVP & Company Secretary
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 October 2026 on Ordinary Shares
held within an ISA
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£17.6650
17
d)
Aggregated
information
Aggregated
volume
Price
N/A (single transaction)
e)
Date
of the transaction
2026-10-09
f)
Place
of the transaction
London Stock Exchange (XLON)
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at
www.gsk.com
.
Registered in England & Wales:
No.
3888792
Registered Office:
79 New Oxford Street
London
WC1A
1DG
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
GSK plc
(Registrant)
Date: October
12, 2026
By:/s/ VICTORIA
WHYTE
--------------------------
Victoria Whyte
Authorised
Signatory for and on
behalf
of GSK plc
6-K
1
a6194y.htm
DIRECTOR/PDMR SHAREHOLDING
a6194y
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of October 2026
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc (the ‘Company’)
Transaction notification
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
Luke Miels
b)
Position/status
Chief Executive Officer
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 October 2026 on shares held
through the Company’s Share Reward Plan
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£17.5852
3
d)
Aggregated
information
Aggregated
volume
Price
N/A (single transaction)
e)
Date
of the transaction
2026-10-08
f)
Place
of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
Lynn Baxter
b)
Position/status
President, Europe
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 October 2026 on shares held
through the Company’s Share Reward Plan
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£17.5852
39
d)
Aggregated
information
Aggregated
volume
Price
N/A (single transaction)
e)
Date
of the transaction
2026-10-08
f)
Place
of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
James Ford
b)
Position/status
SVP and Group General Counsel, Legal and Compliance
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 October 2026 on shares held
through the Company’s Share Reward Plan
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£17.5852
13
d)
Aggregated
information
Aggregated
volume
Price
N/A (single transaction)
e)
Date
of the transaction
2026-10-08
f)
Place
of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
David Redfern
b)
Position/status
President Corporate Development
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 October 2026 on shares held
through the Company’s Share Reward Plan
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£17.5852
80
d)
Aggregated
information
Aggregated
volume
Price
N/A (single transaction)
e)
Date
of the transaction
2026-10-08
f)
Place
of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
Regis Simard
b)
Position/status
President, Global Supply Chain
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 October 2026 on shares held
through the Company’s Share Reward Plan
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£17.5852
32
d)
Aggregated
information
Aggregated
volume
Price
N/A (single transaction)
e)
Date
of the transaction
2026-10-08
f)
Place
of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
Philip Thomson
b)
Position/status
President, Global Affairs
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 October 2026 on shares held
through the Company’s Share Reward Plan
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£17.5852
52
d)
Aggregated
information
N/A (single transaction)
Aggregated
volume
Price
e)
Date
of the transaction
2026-10-08
f)
Place
of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
Deborah Waterhouse
b)
Position/status
CEO, ViiV Healthcare and President, Global Health, GSK
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 October 2026 on shares held
through the Company’s Share Reward Plan
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£17.5852
66
d)
Aggregated
information
Aggregated
volume
Price
N/A (single transaction)
e)
Date
of the transaction
2026-10-08
f)
Place
of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
Victoria Whyte
b)
Position/status
SVP & Company Secretary
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 October 2026 on shares held
through the Company’s Share Reward Plan
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£17.5852
62
d)
Aggregated
information
Aggregated
volume
Price
N/A (single transaction)
e)
Date
of the transaction
2026-10-08
f)
Place
of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
Neil Falkingham
b)
Position/status
PCA of Lynn Baxter (President, Europe)
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 October 2026 on shares held
through the Company’s Share Reward Plan
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£17.5852
64
d)
Aggregated
information
Aggregated
volume
Price
N/A (single transaction)
e)
Date
of the transaction
2026-10-08
f)
Place
of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
Victoria Whyte
b)
Position/status
SVP & Company Secretary
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 October 2026
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£17.5904
243
d)
Aggregated
information
Aggregated
volume
Price
N/A (single transaction)
e)
Date
of the transaction
2026-10-08
f)
Place
of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
Iain Whyte
b)
Position/status
PCA of Victoria Whyte (SVP & Company Secretary)
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 October 2026
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£17.5904
1,182
d)
Aggregated
information
Aggregated
volume
Price
N/A (single transaction)
e)
Date
of the transaction
2026-10-08
f)
Place
of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
Maya Martinez-Davis
b)
Position/status
President, US
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
American Depositary Shares (‘ADS’)
ISIN: US37733W2044
b)
Nature
of the transaction
Acquisition of notional ADS within Ms Martinez-Davis’s GSK
Executive Supplemental Savings Plan account
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
$47.0200
10.155
d)
Aggregated
information
Aggregated
volume
Price
N/A (single transaction)
e)
Date
of the transaction
2026-10-07
f)
Place
of the transaction
New York Stock Exchange (XNYS)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
Lynn Baxter
b)
Position/status
President, Europe
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
Acquisition of Ordinary Shares under the Company’s Share
Reward Plan
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£17.6539
7 (partnership shares)
£17.6539
7 (matching shares)
d)
Aggregated
information
Aggregated
volume
Price
14 Ordinary Shares
£17.6539
e)
Date
of the transaction
2026-10-09
f)
Place
of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
Julie Brown
b)
Position/status
Chief Financial Officer
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
Acquisition of Ordinary Shares under the Company’s Share
Reward Plan
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£17.6539
7 (partnership shares)
£17.6539
7 (matching shares)
d)
Aggregated
information
Aggregated
volume
Price
14 Ordinary Shares
£17.6539
e)
Date
of the transaction
2026-10-09
f)
Place
of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
James Ford
b)
Position/status
SVP and Group General Counsel, Legal and Compliance
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
Acquisition of Ordinary Shares under the Company’s Share
Reward Plan
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£17.6539
7 (partnership shares)
£17.6539
7 (matching shares)
d)
Aggregated
information
Aggregated
volume
Price
14 Ordinary Shares
£17.6539
e)
Date
of the transaction
2026-10-09
f)
Place
of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
David Redfern
b)
Position/status
President, Corporate Development
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
Acquisition of Ordinary Shares under the Company’s Share
Reward Plan
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£17.6539
7 (partnership shares)
£17.6539
7 (matching shares)
d)
Aggregated
information
Aggregated
volume
Price
14 Ordinary Shares
£17.6539
e)
Date
of the transaction
2026-10-09
f)
Place
of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
Regis Simard
b)
Position/status
President, Global Supply Chain
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
Acquisition of Ordinary Shares under the Company’s Share
Reward Plan
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£17.6539
7 (partnership shares)
£17.6539
7 (matching shares)
d)
Aggregated
information
Aggregated
volume
Price
14
Ordinary Shares
£17.6539
e)
Date
of the transaction
2026-10-09
f)
Place
of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
Philip Thomson
b)
Position/status
President, Global Affairs
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
Acquisition of Ordinary Shares under the Company’s Share
Reward Plan
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£17.6539
7 (partnership shares)
£17.6539
7 (matching shares)
d)
Aggregated
information
Aggregated
volume
Price
14 Ordinary Shares
£17.6539
e)
Date
of the transaction
2026-10-09
f)
Place
of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
Deborah Waterhouse
b)
Position/status
CEO, ViiV Healthcare and President, Global Health, GSK
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
Acquisition of Ordinary Shares under the Company’s Share
Reward Plan
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£17.6539
7 (partnership shares)
£17.6539
7 (matching shares)
d)
Aggregated
information
Aggregated
volume
Price
14 Ordinary Shares
£17.6539
e)
Date
of the transaction
2026-10-09
f)
Place
of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
Victoria Whyte
b)
Position/status
SVP & Company Secretary
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
Acquisition of Ordinary Shares under the Company’s Share
Reward Plan
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£17.6539
7 (partnership shares)
£17.6539
7 (matching shares)
d)
Aggregated
information
Aggregated
volume
Price
14 Ordinary Shares
£17.6539
e)
Date
of the transaction
2026-10-09
f)
Place
of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
Neil Falkingham
b)
Position/status
PCA of Lynn Baxter (President, Europe)
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
Acquisition of Ordinary Shares under the Company’s Share
Reward Plan
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£17.6539
7 (partnership shares)
£17.6539
7 (matching shares)
d)
Aggregated
information
Aggregated
volume
Price
14 Ordinary Shares
£17.6539
e)
Date
of the transaction
2026-10-09
f)
Place
of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
David Redfern
b)
Position/status
President Corporate Development
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 October 2026
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£17.6650
7
d)
Aggregated
information
Aggregated
volume
Price
N/A (single transaction)
e)
Date
of the transaction
2026-10-09
f)
Place
of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
Neil Falkingham
b)
Position/status
PCA of Lynn Baxter (President, Europe)
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 October 2026
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£17.6650
7
d)
Aggregated
information
Aggregated
volume
Price
N/A (single transaction)
e)
Date
of the transaction
2026-10-09
f)
Place
of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
David Redfern
b)
Position/status
President Corporate Development
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 October 2026 on Ordinary Shares
held within an ISA
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£17.6650
20
d)
Aggregated
information
Aggregated
volume
Price
N/A (single transaction)
e)
Date
of the transaction
2026-10-09
f)
Place
of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
Victoria Whyte
b)
Position/status
SVP & Company Secretary
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 October 2026 on Ordinary Shares
held within an ISA
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£17.6650
17
d)
Aggregated
information
Aggregated
volume
Price
N/A (single transaction)
e)
Date
of the transaction
2026-10-09
f)
Place
of the transaction
London Stock Exchange (XLON)
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at
www.gsk.com
.
Registered in England & Wales:
No.
3888792
Registered Office:
79 New Oxford Street
London
WC1A
1DG
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
GSK plc
(Registrant)
Date: October
12, 2026
By:/s/ VICTORIA
WHYTE
--------------------------
Victoria Whyte
Authorised
Signatory for and on
behalf
of GSK plc
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
73de602f60· 2026-10-13 18:29 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前